HGFR/c-MET [p Tyr1349] Antibody (EP2367Y)

Product Discontinued

HGFR/c-MET [p Tyr1349] Antibody (EP2367Y) Summary

• Immunogen: A phospho specific peptide corresponding to residues surrounding tyrosine 1349 of human Met was used as an immunogen.
• Modification: p Tyr1349
• Specificity: This antibody detects Met phosphorylated at tyrosine 1349.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: MET
• Purity: Tissue culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 1:50-100
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 1:50-100
  • Immunoprecipitation 1:20
  • Western Blot 1:1000-10000
• Application Notes: In Western blot this antibody detects a band at approximately 145kDa.
• Theoretical MW: 145 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reactivity Notes

Mouse reactivity reported in scientific literature (PMID: 24097861)

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: 49% PBS, 0.05% BSA and 50% Glycerol
• Preservative: 0.01% Sodium Azide
• Purity: Tissue culture supernatant

Notes

Produced using Abcam's RabMab® technology. RabMab® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

Alternate Names for HGFR/c-MET [p Tyr1349] Antibody (EP2367Y)

• AUTS9
• cMET
• c-MET
• EC 2.7.10
• EC 2.7.10.1
• hepatocyte growth factor receptor
• HGF R
• HGF receptor
• HGF/SF receptor
• HGFR
• Met (c-Met)
• met proto-oncogene (hepatocyte growth factor receptor)
• met proto-oncogene tyrosine kinase
• MET
• oncogene MET
• Proto-oncogene c-Met
• RCCP2
• Scatter factor receptor
• SF receptor
• Tyrosine-protein kinase Met

Background

Met is a receptor protein-tyrosine kinase (RPTK) for hepatocyte growth factor (HGF), which is a multifunctional cytokine controlling cell growth, morphogenesis, and motility. Met overexpression has been identified in a variety of human cancers (1). Met kinase domain possesses unique features that distinguish met from other members of the src family of protein tyrosine kinases. These results also demonstrate that the product of the activated met gene is a fusion protein and that the amino terminal end of this fusion protein exhibits homology to laminin B1 (2). Data suggest that RanBP9, functioning as an adaptor protein for the Met tyrosine kinase domain, can augment the HGF-Met signaling pathway and that RanBP9 overexpression may cause constitutive activation of the Ras signaling pathway (1). Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer Results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the Met protein and papillary renal carcinomas (3)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for HGFR/c-MET Antibody (NBP1-40436)(2)

Publications using NBP1-40436

• Efstathiou E, Titus M, Wen S et al. Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. Eur. Urol. 2014-05-29 [PMID: 24882673] (IHC-P, Human)
• Dai J, Zhang H, Karatsinides A et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res 2013-10-04 [PMID: 24097861] (Immunohistochemistry-Paraffin, Human)

Bioinformatics

• Gene Symbol: MET
• Entrez:
  • 4233(Human)
• Uniprot:
  • P08581()